Cargando…
Early antibody responses associated with survival in COVID19 patients
Neutralizing antibodies to the SARS CoV-2 spike proteins have been issued Emergency Use Authorizations and are a likely mechanism of vaccines to prevent COVID-19. However, benefit of treatment with monoclonal antibodies has only been observed in clinical trials in outpatients with mild to moderate C...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8321400/ https://www.ncbi.nlm.nih.gov/pubmed/34280244 http://dx.doi.org/10.1371/journal.ppat.1009766 |
_version_ | 1783730842133069824 |
---|---|
author | Zhou, Zhao-Hua Dharmarajan, Sai Lehtimaki, Mari Kirshner, Susan L. Kozlowski, Steven |
author_facet | Zhou, Zhao-Hua Dharmarajan, Sai Lehtimaki, Mari Kirshner, Susan L. Kozlowski, Steven |
author_sort | Zhou, Zhao-Hua |
collection | PubMed |
description | Neutralizing antibodies to the SARS CoV-2 spike proteins have been issued Emergency Use Authorizations and are a likely mechanism of vaccines to prevent COVID-19. However, benefit of treatment with monoclonal antibodies has only been observed in clinical trials in outpatients with mild to moderate COVID-19 but not in patients who are hospitalized and/or have advanced disease. To address this observation, we evaluated the timing of anti SARS-CoV-2 antibody production in hospitalized patients with the use of a highly sensitive multiplexed bead-based immunoassay allowing for early detection of antibodies to SARS-CoV-2. We found significantly lower levels of antibodies to the SARS-CoV-2 spike protein in the first week after symptom onset in patients who expired as compared to patients who were discharged. We also developed a model to characterize the relationship between each patient’s individual antibody level trajectory and eventual COVID 19 outcome which can be adapted into a prediction model with more data. |
format | Online Article Text |
id | pubmed-8321400 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-83214002021-07-31 Early antibody responses associated with survival in COVID19 patients Zhou, Zhao-Hua Dharmarajan, Sai Lehtimaki, Mari Kirshner, Susan L. Kozlowski, Steven PLoS Pathog Research Article Neutralizing antibodies to the SARS CoV-2 spike proteins have been issued Emergency Use Authorizations and are a likely mechanism of vaccines to prevent COVID-19. However, benefit of treatment with monoclonal antibodies has only been observed in clinical trials in outpatients with mild to moderate COVID-19 but not in patients who are hospitalized and/or have advanced disease. To address this observation, we evaluated the timing of anti SARS-CoV-2 antibody production in hospitalized patients with the use of a highly sensitive multiplexed bead-based immunoassay allowing for early detection of antibodies to SARS-CoV-2. We found significantly lower levels of antibodies to the SARS-CoV-2 spike protein in the first week after symptom onset in patients who expired as compared to patients who were discharged. We also developed a model to characterize the relationship between each patient’s individual antibody level trajectory and eventual COVID 19 outcome which can be adapted into a prediction model with more data. Public Library of Science 2021-07-19 /pmc/articles/PMC8321400/ /pubmed/34280244 http://dx.doi.org/10.1371/journal.ppat.1009766 Text en https://creativecommons.org/publicdomain/zero/1.0/This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 (https://creativecommons.org/publicdomain/zero/1.0/) public domain dedication. |
spellingShingle | Research Article Zhou, Zhao-Hua Dharmarajan, Sai Lehtimaki, Mari Kirshner, Susan L. Kozlowski, Steven Early antibody responses associated with survival in COVID19 patients |
title | Early antibody responses associated with survival in COVID19 patients |
title_full | Early antibody responses associated with survival in COVID19 patients |
title_fullStr | Early antibody responses associated with survival in COVID19 patients |
title_full_unstemmed | Early antibody responses associated with survival in COVID19 patients |
title_short | Early antibody responses associated with survival in COVID19 patients |
title_sort | early antibody responses associated with survival in covid19 patients |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8321400/ https://www.ncbi.nlm.nih.gov/pubmed/34280244 http://dx.doi.org/10.1371/journal.ppat.1009766 |
work_keys_str_mv | AT zhouzhaohua earlyantibodyresponsesassociatedwithsurvivalincovid19patients AT dharmarajansai earlyantibodyresponsesassociatedwithsurvivalincovid19patients AT lehtimakimari earlyantibodyresponsesassociatedwithsurvivalincovid19patients AT kirshnersusanl earlyantibodyresponsesassociatedwithsurvivalincovid19patients AT kozlowskisteven earlyantibodyresponsesassociatedwithsurvivalincovid19patients |